#USA #San Diego #Antibody Discovery #FairJourney Bio #Sapio AI Platform

FairJourney Bio Streamlines Antibody Discovery with Sapio's AI

In a significant move to enhance its operations, FairJourney Bio (FJBio), a leading expert in antibody discovery, has integrated the Sapio Scientific AI Platform into its workflows. This strategic choice marks a new chapter in how FJBio manages and processes complex data across its global operations, which span key locations in Cambridge, Porto, and San Diego.

Established in 2012, FairJourney Bio has built a formidable reputation in the biotechnology sector, having completed over 1,400 programs for more than 250 partners in industries like pharma and academia. With 20 partner assets currently in clinical trials, the pressure to deliver consistent, high-quality data has never been greater. The complexity of experimental data generated necessitated a streamlined, standardized approach to ensure operational efficiency.

Unifying Data Management

The adoption of Sapio's LIMS (Laboratory Information Management System) and ELN (Electronic Lab Notebook) solutions allows FJBio to replace outdated, paper-based data capture systems. By transitioning to a unified digital platform, scientists will benefit from real-time access to experimental data and insights, enhancing collaboration and accelerating program timelines. The new system also integrates input from ten laboratory instruments directly into the Sapio platform, significantly reducing the risk of errors from manual data entry.

By consolidating its informatics framework under one roof, FJBio aims to free up approximately 40% of its scientific staff's time—allowing researchers to devote more attention to the discovery process instead of mundane data consolidation tasks. As Mike Hampton, Chief Commercial Officer at Sapio Sciences, stated, this synergy not only boosts productivity but also enriches the scientific output that FJBio provides to its clients.

Strategic Infrastructure for Growth

Choosing the Sapio Scientific AI Platform came as a result of FJBio's comprehensive evaluation of its informatics infrastructure. With operations spanning three international sites, having a connected, cohesive environment was essential. The depth of the Sapio platform’s capabilities provides the flexibility FJBio needs to maintain traceability throughout the entire discovery process—from target registration to screening and hit identification.

The platform includes Elain, an advanced AI co-scientist that aids researchers by simplifying data interaction. Elain enables scientists to communicate with their data seamlessly, providing insights, generating reports, and automating repetitive tasks directly within FJBio's research environment. This integration can potentially revolutionize how FJBio's scientists work, dramatically improving productivity and accelerating the pace of antibody discovery.

Future-Focused Discoveries

FairJourney Bio's commitment to maintaining high-quality data integrity is evident in its stringent standards for data security and traceability. As José Vidal, Chief Operations Officer, noted, the value clients place on robust, consistent data during each stage of the discovery process is paramount. The integration of the Sapio Platform aims to uphold these standards while scaling up the company’s operations.

Moreover, FJBio's strategic expansion into the U.S. market, powered by investment from Partners Group in 2024, has further solidified its position as a frontrunner in the antibody discovery field. With the establishment of a cutting-edge structural biology hub in San Diego, the company is poised to leverage its new informatics platform to enhance its antibody design capabilities.

This progressive step forward exemplifies FJBio's dedication to innovation and excellence in science, fostering a collaborative, efficient environment that can efficiently adapt to changing demands in the biotech landscape. With the Sapio Scientific AI Platform now in place, FairJourney Bio is well-equipped to lead the charge in antibody discovery for years to come.